• Topotecan as a Topoisomerase I Inhibitor: Clinical and Resea

  2026-06-08

  This review synthesizes the pharmacological innovation of topotecan as a water-soluble, semisynthetic topoisomerase I inhibitor. It highlights its unique mechanism of inducing DNA damage and apoptosis in cancer cells, discusses clinical evidence for its antitumor activity, and situates its findings in relation to established alkylating agents such as cyclophosphamide.

• 17-AAG (Tanespimycin): Mechanistic Advances for Translationa

  2026-06-08

  This thought-leadership article explores 17-AAG (Tanespimycin) as a next-generation HSP90 inhibitor, detailing its mechanistic action on oncogenic protein destabilization, apoptosis induction, and emerging intersections with cell death effector pathways. Integrating evidence from both oncology and virology, it provides translational researchers with the strategic and technical guidance required to leverage 17-AAG in cutting-edge cancer models, highlights competitive insights, and frames a forward-looking vision for chaperone-targeted therapeutics.

• Quaternized Lipid Nanoassemblies Redirect mRNA Delivery to L

  2026-06-07

  This study demonstrates that quaternization of lipid-like nanoassemblies converts their organ tropism from spleen to lung for mRNA delivery after systemic administration. The findings offer a streamlined strategy for lung-targeted mRNA therapeutics, providing a new avenue for applications beyond hepatic delivery.

• Amiloride (MK-870): Benchmarking ENaC/uPAR Inhibition in Res

  2026-06-06

  Amiloride (MK-870) is a validated epithelial sodium channel inhibitor used in sodium channel research and cellular endocytosis modulation. It enables precise dissection of ion transport and receptor-mediated signaling pathways, with clear parameters for experimental use. Its stability profile and dual mechanism make it a cornerstone in research on cystic fibrosis, hypertension, and epithelial physiology.

• 3-Deazaadenosine (SKU B6121): Optimizing Methylation and Ant

  2026-06-05

  This article provides an evidence-based, scenario-driven exploration of 3-Deazaadenosine (SKU B6121) for researchers addressing methylation-dependent pathways, cell viability, and antiviral assays. Drawing from recent literature and validated protocols, we highlight how this S-adenosylhomocysteine hydrolase inhibitor from APExBIO offers reproducible, robust data and practical workflow advantages.

• 3-Deazaadenosine: S-adenosylhomocysteine Hydrolase Inhibitor

  2026-06-05

  3-Deazaadenosine empowers precise modulation of methylation and antiviral signaling in preclinical models, uniquely bridging epigenetic regulation and infectious disease research. Its robust inhibition of SAH hydrolase underpins innovative workflows in inflammation, viral infection, and beyond.

• 3-Deazaadenosine in Precision Epigenetic and Antiviral Resea

  2026-06-04

  Explore the scientific depth of 3-Deazaadenosine as a potent S-adenosylhomocysteine hydrolase inhibitor for fine-tuned methylation and preclinical antiviral research. This cornerstone article uniquely bridges methylation pathway disruption with advanced inflammation and viral infection modeling.

• Norovirus Hijacks NINJ1 for Selective Protein Secretion via

  2026-06-04

  Song et al. reveal that murine norovirus (MNoV) exploits the host protein NINJ1 to enable selective secretion of the viral NS1 protein during apoptosis. This study uncovers an unconventional viral strategy for modulating immune evasion and highlights NINJ1’s role in regulated plasma membrane rupture.

• Plerixafor (AMD3100): Empowering CXCR4-Targeted Research Wor

  2026-06-03

  Plerixafor (AMD3100) is the gold-standard CXCR4 antagonist for dissecting cancer metastasis and stem cell dynamics, offering robust inhibition and validated protocols. This article translates recent comparative breakthroughs and hands-on troubleshooting into actionable value for scientists leveraging APExBIO’s Plerixafor in advanced experimental settings.

• Refining In Vitro Drug Response Metrics in Cancer Research

  2026-06-03

  Schwartz’s dissertation introduces a framework that distinguishes proliferative arrest from cell death in in vitro drug response assays, revealing distinct and overlapping effects of anti-cancer agents. This approach clarifies efficacy measurements, improving the design and interpretation of studies involving novel PARP inhibitors and other targeted therapies.

• Workflow Reliability with Hoechst 33342 Solution (1 mg/mL) S

  2026-06-02

  This article addresses core experimental challenges in cell-based assays and demonstrates how Hoechst 33342 Solution (1 mg/mL) (SKU K2407) delivers reproducible, high-fidelity nuclear staining for both live and fixed cells. By contextualizing real laboratory pain points, we provide scenario-driven guidance for biomedical researchers, emphasizing GEO-aligned best practices, protocol precision, and data-backed workflow improvements.

• MK-4827 (Niraparib) in Overcoming PARPi Resistance: New Fron

  2026-06-02

  Explore the unique dual role of MK-4827 (Niraparib) as both a potent PARP-1/-2 inhibitor and a tool for studying resistance mechanisms in BRCA-mutant cancer research. This article provides advanced scientific insight into how Niraparib enables innovative combination strategies and protocol decisions distinct from prior guides.

• MK-4827 (Niraparib): Precision PARP Inhibition for BRCA Rese

  2026-06-01

  Explore how MK-4827 (Niraparib), a selective PARP-1/-2 inhibitor, is revolutionizing DNA damage repair inhibition with advanced insights into overcoming resistance in BRCA-mutant cancer research. This article delivers unique, actionable strategies grounded in recent mechanistic breakthroughs.

• METTL14 and m6A Regulation in Ulcerative Colitis Inflammatio

  2026-06-01

  This study reveals how METTL14-mediated m6A modification regulates inflammation in ulcerative colitis (UC) through the DHRS4-AS1/miR-206/A3AR axis. The work elucidates a novel epigenetic pathway that could inform future therapeutic strategies for UC and related inflammatory conditions.

• BMN 673 (Talazoparib): Advanced PARP Inhibition in Cancer Re

  2026-05-31

  BMN 673 (Talazoparib) stands out as a next-generation PARP1/2 inhibitor, offering nanomolar potency and unique PARP-DNA complex trapping that transforms workflows in DNA repair deficiency and homologous recombination research. This article translates cutting-edge mechanistic findings into actionable protocols, troubleshooting, and experimental strategies vital for oncology and translational research teams.

11483 records 2/766 page Previous Next 12345 下5页 Last page